Type to search

Levi Garraway

Share
Levi Garraway
Executive Vice President, Head of Global Product Development and Chief Medical Officer
Roche

Levi Garraway

As the chief medical officer at Roche and Genentech, I lead global product development and work with highly talented and motivated teams from around the world. Together, we follow the science and pursue therapeutic breakthroughs that will help people with many types of challenging diseases.

Over the course of my career, I have worn the hats of the clinician, teacher, biomedical researcher, team builder, and drug development leader. My passion for bringing scientific advances forward to benefit patients ultimately led me to make the “jump” from academia to industry, where knowledge of disease biology is driving new therapeutic advances at an increasingly rapid rate.

Today, cutting-edge technologies and analytics are helping us both to gain a higher resolution understanding of disease and to develop medicines and solutions that enable more individualized care. At Roche and Genentech, our ultimate goal is to transform the bold vision of personalized healthcare into a reality for people everywhere.

Posts Featuring Levi Garraway


Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: addcslashes() expects parameter 1 to be string, array given in /home/customer/www/pharmtechfocus.com/public_html/wp-includes/class-wpdb.php on line 1562
European Commission Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss | Pharmtech Focus

European Commission Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss

FDA Accepts Supplemental Biologics License Application for Roche’s Polivy Combination for People With Previously Untreated Diffuse Large B-cell Lymphoma | Pharmtech Focus

FDA Accepts Supplemental Biologics License Application for Roche’s Polivy Combination for People With Previously Untreated Diffuse Large B-cell Lymphoma

CHMP Recommends EU Approval of Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss | Pharmtech Focus

CHMP Recommends EU Approval of Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss

New Two-year Data Confirm Roche’s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration | Pharmtech Focus

New Two-year Data Confirm Roche’s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration

European Commission Approves Roche’s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer | Pharmtech Focus

European Commission Approves Roche’s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer

European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma | Pharmtech Focus

European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma

FDA Approves Roche’s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA) | Pharmtech Focus

FDA Approves Roche’s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)

New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma | Pharmtech Focus

New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma

Roche’s Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma | Pharmtech Focus

Roche’s Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma

CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer | Pharmtech Focus

CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer

U.S. FDA Grants Priority Review to Roche’s Actemra/Roactemra for the Treatment of COVID-19 in Hospitalised Adults | Pharmtech Focus

U.S. FDA Grants Priority Review to Roche’s Actemra/Roactemra for the Treatment of COVID-19 in Hospitalised Adults

Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer | Pharmtech Focus

Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer

New Data for Roche’s Evrysdi (risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People with Spinal Muscular Atrophy (SMA) | Pharmtech Focus

New Data for Roche’s Evrysdi (risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People with Spinal Muscular Atrophy (SMA)

New Two-year Data for Roche’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision with Fewer Treatments for People with Two Leading Causes of Vision Loss | Pharmtech Focus

New Two-year Data for Roche’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision with Fewer Treatments for People with Two Leading Causes of Vision Loss

FDA Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss | Pharmtech Focus

FDA Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

Roche’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-symptomatic Babies Under 2 Months of Age with Spinal Muscular Atrophy (SMA) | Pharmtech Focus

Roche’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-symptomatic Babies Under 2 Months of Age with Spinal Muscular Atrophy (SMA)

CHMP Recommends EU Approval of Actemra/RoActemra to Treat Patients with Severe COVID-19 | Pharmtech Focus

CHMP Recommends EU Approval of Actemra/RoActemra to Treat Patients with Severe COVID-19

US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer | Pharmtech Focus

US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer

FDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) | Pharmtech Focus

FDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

New Data for Roche’s Hemlibra Reinforce Safety Profile in People with Haemophilia A | Pharmtech Focus

New Data for Roche’s Hemlibra Reinforce Safety Profile in People with Haemophilia A

Roche’s ENSPRYNG Approved by European Commission as First and Only At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD) | Pharmtech Focus

Roche’s ENSPRYNG Approved by European Commission as First and Only At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year and Confirm Safety Profile in Previously Treated People with Spinal Muscular Atrophy (SMA) | Pharmtech Focus

New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year

European Commission Approves Venclyxto-based Combinations for Adults with Newly Diagnosed Acute Myeloid Leukaemia Who Are Ineligible for Intensive Chemotherapy | Pharmtech Focus

European Commission Approves Venclyxto-based Combinations for Adults with Newly Diagnosed Acute Myeloid Leukaemia Who Are Ineligible for Intensive Chemotherapy

Roche’s Tecentriq Approved by European Commission as a First-line Monotherapy Treatment for People with a Type of Metastatic Non-small Cell Lung Cancer | Pharmtech Focus

Roche’s Tecentriq Approved by European Commission

New Roche Data at 2021 AAN Highlight Neuroscience Portfolio | Pharmtech Focus

New Roche Data at 2021 AAN Highlight Neuroscience Portfolio